| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Sagent Pharmaceuticals is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Unisource NTC is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leading The Future of Cannabis
DocShop Pro provides the best prices for supplies for doctors, as well as an inventory management system for practice managers. Join DocShop Pro today!